Gildeuretinol Receives FDA Designations for Stargardt Disease Treatment: TEASE Trials Show Promise
Credit: Vitreo Retinal Associates Gildeuretinol (ALK-001), an innovative investigational oral therapy developed by Alkeus Pharmaceuticals, has attained prestigious Rare Pediatric Disease and Fast Track designations